Skip to main content
Log in

Successful Treatment of Progressive NK cell Lymphoma with Allogeneic Peripheral Stem Cell Transplantation Followed by Early Cyclosporine Tapering and Donor Leukocyte Infusions

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

We describe a patient with progressive natural killer (NK) cell lymphoma who was treated successfully with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) followed by early cyclosporine (CsA) tapering and donor leukocyte infusion (DLI). Because the disease showed early resistance to conventional chemoradiotherapy, we performed high-dose chemotherapy followed by allo-PBSCT. After achieving hematologic engraftment, the patient underwent early tapering of CsA and DLI in an attempt to induce a graft-versus-lymphoma effect. Although the disease was in a progressive state at the time of transplantation, complete remission was obtained after allo-PBSCT. As of this report, the patient has been well for more than 2 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/ leukemia: pathology and treatment.Hematol Oncol. 1997;15:71–79.

    Article  PubMed  CAS  Google Scholar 

  2. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma.Blood. 1994; 84:1050–1055.

    Article  PubMed  CAS  Google Scholar 

  3. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma.Bone Marrow Transplant. 1997;19:121–127.

    Article  PubMed  Google Scholar 

  4. Harada M, Nagafuji K, Fujisaki T, et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation.J Hematother. 1996;5:63–71.

    Article  PubMed  CAS  Google Scholar 

  5. Oji Y, Oka Y, Tatekawa T, et al. Successful treatment of relapsed T-cell non-Hodgkin’s lymphoma with allogeneic peripheral blood stem cell transplantation with double conditioning.Int J Hematol. 1999;69:263–267.

    PubMed  CAS  Google Scholar 

  6. Nawa Y, Takenaka K, Shinagawa K, et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation.Bone Marrow Transplant. 1999;23:1321–1322.

    Article  PubMed  CAS  Google Scholar 

  7. Takami A, Nakao S, Yachie A, et al. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation.Bone Marrow Transplant. 1998;21:1279–1282.

    Article  PubMed  CAS  Google Scholar 

  8. Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell- large granular lymphocyte leukaemia.Lancet. 1996;347:1124.

    Article  PubMed  CAS  Google Scholar 

  9. Carlens S, Aschan J, Remberger M, Dilber M, Ringden O. Low- dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia.Bone Marrow Transplant. 1999;24:629–635.

    Article  PubMed  CAS  Google Scholar 

  10. Abraham R, Szer J, Bardy P, Grigg A. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.Bone Marrow Transplant. 1997;20:773–777.

    Article  PubMed  CAS  Google Scholar 

  11. Aschan J, Ringden O,Andstrom E, Ljungman P, Lonnqvist B, Remberger M. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.Bone Marrow Transplant. 1994;14:79–87.

    PubMed  CAS  Google Scholar 

  12. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation: EBMT Immunology and Chronic Leukemia Working Parties.Vox Sang. 1998;74: 321–329.

    Article  PubMed  CAS  Google Scholar 

  13. de Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.Bone Marrow Transplant. 2001;27:73–78.

    Article  PubMed  Google Scholar 

  14. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.Blood. 1995;86:1261–1268.

    Article  PubMed  CAS  Google Scholar 

  15. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho- proliferative disorders after allogeneic bone marrow transplantation.N Engl J Med. 1994;330:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  16. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.Blood. 1997;90:4206–4211.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masanori Makita.

About this article

Cite this article

Makita, M., Maeda, Y., Takenaka, K. et al. Successful Treatment of Progressive NK cell Lymphoma with Allogeneic Peripheral Stem Cell Transplantation Followed by Early Cyclosporine Tapering and Donor Leukocyte Infusions. Int J Hematol 76, 94–97 (2002). https://doi.org/10.1007/BF02982726

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02982726

Key words

Navigation